Barely Significant
← all excerpts

Efficacy and safety of regorafenib plus FOLFIRI with <i>UGT1A1</i> genotyping-guided irinotecan dose escalation against metastatic colorectal cancer: a multicenter, phase II, open-label, two-arm randomized controlled tria.

Ther Adv Med Oncol · 2025 · PMC12559644 · PMID 41164204

Europe PMCDOI
2
hedged sentences
0.0550
closest p · 1.1× alpha
0.8080
boldest claim

The sentences

marginally significantp = 0.055so close (0.05 < p ≤ 0.1)
The experimental group exhibited significant improvement in PFS ( p = 0.016) but marginally significant improvements in DCR ( p = 0.055).

also in 26,082 other papers

did not reach statistical significancep = 0.808not close (p > 0.1)
As shown in Table 3 , tumor location (right- vs left-sided) did not reach statistical significance for OS in either univariate analysis (HR = 0.936, 95% CI: 0.548–1.598; p = 0.808) or multivariable analysis (HR = 0.873, 95% CI: 0.477–1.596; p = 0.873).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.